microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer

Zedan, Ahmed; Hansen, Torben Frøstrup; Assenholt, Jannie; Pleckaitis, Mindaugas; Madsen, Jonna Skov; Osther, Palle Jørn Sloth

doi:10.1177/1010428318775864

Cited by 43 publications

(43 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… a Data regarding miRNA‐93 in both intervention and observation cohort was published in our previous work (ref. ).…”

Section: Resultsmentioning

confidence: 97%

“…*Box plots regarding miRNA‐93 in both intervention and observation cohort was published in our previous work (ref. ). [Color figure can be viewed at wileyonlinelibrary.com]…”

Section: Resultsmentioning

confidence: 97%

“…As described in our previous work (validation cohort), all patients were referred to the Department of Urology either at Vejle Hospital or Esbjerg Hospital, Denmark, between September 2015 and May 2017. All participants provided informed written consent.…”

Section: Methodsmentioning

confidence: 99%

“…Based on the validation cohort from our previous work, microRNA purification from PPP was performed using the Maxwell RSC miRNA Tissue Kit (AS1460) verified for plasma use (Scientific Style and Format, 7th edition, 2006). Two hundred microliter plasma was mixed with 200 μL chilled 1‐Thioglycerol/Homogenization Solution and 200 μL lysis solution.…”

Section: Methodsmentioning

confidence: 99%

“…We have previously established both miRNA‐17 and miRNA‐191 as suitable internal controls, that is, they displayed stable expression levels throughout all previous samples as judged by manual review and according to the Normfinder algorithm . Both miRNAs had previously proven suitable as reference RNA targets .…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background Overtreatment is a well‐known clinical challenge in local prostate cancer (PCa). Although risk assessment models have contributed to a better stratification of patients with local PCa, a tailored management is still in its infancy. Over the last few decades, microRNAs (miRNAs) have shown promising results as biomarkers in PCa. The aim of this study was to investigate circulating miRNAs after management of local PCa. Methods The relative expression of four miRNAs (miRNA‐21, ‐93, ‐125b, and miRNA‐221) was assessed in plasma from 149 newly diagnosed patients with local or locally advanced PCa. Real‐time polymerase chain reaction was used for analysis. A baseline sample at time of diagnosis and a follow‐up sample after 6 months were assessed. The patients were grouped in an interventional cohort (radical prostatectomy, curative intent radiotherapy, or androgen‐deprivation therapy alone) and an observational cohort (watchful waiting or active surveillance). Results In the interventional cohort, levels of both miRNA‐93 and miRNA‐221 were significantly lower in the follow‐up samples compared to baseline z = −2.738, P = 0.006, and z = −4.498, P < 0.001, respectively. The same observation was recorded for miRNA‐125b in the observational cohort ( z = −2.656, P = 0.008). Both miRNA‐125b and miRNA‐221 were correlated with risk assessment r = 0.23, P = 0.015, and r = 0.203, P = 0.016 respectively, while miRNA‐93 showed tendency to significant correlation with the prostatectomy Gleason score ( r = 0.276, P = 0.0576). Conclusions The current results indicate a possible role of miRNA‐93 and miRNA‐221 in disease monitoring in localized and locally advanced PCa. Larger studies are warranted to assess the clinical impact of these biomarkers.

show abstract

“… a Data regarding miRNA‐93 in both intervention and observation cohort was published in our previous work (ref. ).…”

Section: Resultsmentioning

confidence: 97%

“…*Box plots regarding miRNA‐93 in both intervention and observation cohort was published in our previous work (ref. ). [Color figure can be viewed at wileyonlinelibrary.com]…”

Section: Resultsmentioning

confidence: 97%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

Adipose tissue from metabolic syndrome mice induces an aberrant miRNA signature highly relevant in prostate cancer development

et al. 2020

View full text Add to dashboard Cite

Prostate cancer (PCa) remains an important public health concern in Western countries. Metabolic syndrome (MeS) is a cluster of pathophysiological disorders with increasing prevalence in the general population that is a risk factor for PCa. Several studies have determined that a crosstalk between white adipose tissue (WAT) and solid tumors favors cancer aggressiveness. In this work, our main goal was to investigate the interaction between WAT and PCa cells through microRNAs (miRNAs), in MeS mice. We developed a MeS-like disease model using C57BL/6J mice chronically fed with high-fat diet (HFD) that were inoculated with TRAMP-C1 PCa cells. A group of five miRNAs (mmu-miR-221-3p, 27a-3p, 34a-5p, 138-5p, and 146a-5p) were increased in gonadal WAT (gWAT), tumors, and plasma of MeS mice compared to control animals. Three of these five miR-NAs were detected in the media from gWAT and TRAMP-C1 cell cocultures, and significantly increased in MeS context. More importantly, hsa-miR-221-3p, 146a-5p, and 27a-3p were increased in bloodstream of PCa patients compared to healthy donors. Using miRNA microarrays, we found that 121 miRNAs were differentially released to the coculture media between HFD-gWAT and tumor cells compared to control diet-gWAT and tumor cells. Target genes for the 66 most deregulated miRNAs were involved in common pathways, mainly related to fatty acid metabolism, ER protein processing, amino acid degradation, PI3K AKT signaling, and PCa. Our findings show for the first time a signature of five miRNAs as important players involved in the interaction between WAT and PCa in MeS mice. Further research will be necessary to track these miRNAs in the interaction between these tissues as well as their role in PCa patients with MeS.

show abstract

Circulating microRNAs as potential diagnostic biomarkers and therapeutic targets in prostate cancer: Current status and future perspectives

Movahedpour

Ahmadi

Ghasemi

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the most common malignancies among men. Despite advancement in technology and medicine over past decades, late diagnosis remains a critical milestone in effective treatment. Therefore, it is necessary to identify novel and reliable biomarkers which are specifically sensitive and specific for prognosis and prediction of clinical outcomes. MicroRNAs (miRNAs) play important roles in posttranslational regulations of genes. Circulating and exosomal miRNAs can be applied as useful diagnostic markers for a different type of malignancies, including PCa. Herein, we summarized various roles of miRNAs (diagnostic, therapeutic, and prognostic) in PCa. Moreover, we highlighted exosomal miRNAs as a new candidate in diagnosis and monitoring response to therapy in patients with PCa.

show abstract

microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer

Cited by 43 publications

References 85 publications

Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy

Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy

Adipose tissue from metabolic syndrome mice induces an aberrant miRNA signature highly relevant in prostate cancer development

Circulating microRNAs as potential diagnostic biomarkers and therapeutic targets in prostate cancer: Current status and future perspectives

Contact Info

Product

Resources

About